At the recent 13th annual meeting of the National Comprehensive Cancer Network (NCCN), a panel of experts released new lung cancer guidelines. The most notable of its updates is that early adjuvant chemotherapy is recommended for patients with non-small cell lung cancer (NSCLC); CT screening for lung cancer is not routinely recommended. The new guidelines state that cisplatin-based adjuvant chemotherapy can reduce the risk of death in patients with stage II&;mdash;III who have undergone resection; adjuvant therapy should also be considered for patients with stage IB. For stage IIIA patients, the new guidelines recommend combination therapy (including radiotherapy) as the standard of care. The new guidelines state that the goal of treatment is cure, and that even in stage IV NSCLC, disease may become chronic as long as multiple effective treatments are targeted in combination. The new guidelines continue to recommend bevacizumab (bevacizumab), arguing that the drug may improve patient survival. However, the panel cautioned that the drug may lead to an increased risk of severe bleeding (including hemoptysis). And the addition of bevacizumab may be inappropriate for patients with other conditions such as a high risk of grade 4 thrombocytopenia.